Pioglitazone

CHEMBL595 Phase 4 Одобрено Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

356.4 g/mol

LogP

3.8

Phase

4

Used to improve blood sugar control in adults with type 2 diabetes by making the body's cells more sensitive to insulin, and also has beneficial effects on cardiovascular risk factors. It is often used in combination with other diabetes medications when blood sugar is not adequately controlled.

Молекулярная масса

356,4000 g/mol

LogP

3,80

TPSA

93,60 Å²

Правило пяти Липинского

Соответствует

Терапевтические области

Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Cardiovascular Disease Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Alzheimer's Disease Parkinson's Disease Schizophrenia Bipolar Disorder Melanoma Psoriasis Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Atopic Dermatitis HIV/AIDS Hepatitis C Heart Failure Prostate Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure

Embed this structure

SMILES

CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1

InChI

InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)

Molecular Formula

C19H20N2O3S

HBD / HBA

1 / 5

Вращаемые Связи

7

Тяжёлые Атомы

25

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Used to improve blood sugar control in adults with type 2 diabetes by making the body's cells more sensitive to insulin, and also has beneficial effects on cardiovascular risk factors. It is often used in combination with other diabetes medications when blood sugar is not adequately controlled.

Yes, Pioglitazone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL595. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4829. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Ищете информацию, доступную для пациентов?

Pioglitazone на PillFYI

Структура

Краткие Данные

Формула: C19H20N2O3S
Синонимы: 5

Внешние ссылки

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.